MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
34.97
+1.49
+4.45%
Pre Market: 36.50 +1.53 +4.38% 08:56 06/10 EDT
OPEN
33.77
PREV CLOSE
33.48
HIGH
35.09
LOW
33.54
VOLUME
2
TURNOVER
0
52 WEEK HIGH
57.99
52 WEEK LOW
25.83
MARKET CAP
3.69B
P/E (TTM)
-6.8126
1D
5D
1M
3M
1Y
5Y
1D
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Weakness
Simply Wall St · 1d ago
Weekly Report: what happened at CRNX last week (0601-0605)?
Weekly Report · 2d ago
Are Crinetics Pharmaceuticals’ (CRNX) ENDO 2026 Data Updates Reframing Its Endocrine Pipeline Strategy?
Simply Wall St · 3d ago
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
Barchart · 06/02 15:05
Crinetics to present up to 2-year PATHFNDR open-label extension data on oral acromegaly drug Palsonify at ENDO 2026
PUBT · 06/02 08:55
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Barchart · 06/02 03:55
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Weakness
Simply Wall St · 06/02 03:26
Weekly Report: what happened at CRNX last week (0525-0529)?
Weekly Report · 06/01 09:07
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.